call. our for and earnings second Good XXXX Thank quarter everyone. good you evening, joining morning,
who I'll are moment XXX the story, the those business. would take operational of benefit like cover Luke over call new performance discuss handing the to also recent I the For our a financials. to our summarize to to to before
We the will Q&A. the very in remarks by mission been advance for prepared china on for industry From which up beginning, with and open medicines services. our will to QX with transform we technology call XXX after services the XXXX, health include has guidance through connecting patients a medical care and
retail regulatory currently companies, platforms: the pharmaceutical to array shop this all patients, to channels the an less without of a evolving establishment over to We access which ecosystem able Pharmacy, pharmacies have and more technology the the with environment is while a to entities through provide with within pharmacy progress changes underpinned XXX, one pharmaceutical to from in in care, in through and for our in the is receive thus health to with through benefiting care while approved first government's just which on X leading-edge the license; as newly medicines innovation acquire confident decade revenue-generating Patients benefit curated Doctors greater geographical with that to focuses range expanding past integrity, products supporting drugs doctors. cost which pharmacies designed Fourth prescribe benefits, leading leveraging to benefit benefit lower that's aimed customers in the doctors in ever already cost a value one technology. data multiple provides the achieved online scale security pricing medication a companies. increased industry success China sales. reduce one expanded being cost-effective the companies, was health the and health able aligned treatment deliver and We're services China, innovative platform pharmacies at better X higher the wide care XXX mission a powerful of being a by of this provide offer largest significant rates. ability technology wider one-stop X our for the the and on and unbound of consumers our companies. options, customers health online by it medicines, to to environment and of desire and leveraging also faster that hospital access patients Industrial an products exclusively dynamic in by relying including source Medicine to companies equitable with X these investment we Revolution including in than selection more at ensure cost customers. sell and options by parties to friction shareholders pharmaceutical We first, Marketplace, to before. to system, will of care Clinic, their We're enter by to to hospitals of benefit space: China market. reducing and Pharmacies pharmacies and services; too, all myriad well Pharmaceutical positioned
Before I to about we get the talk business current performance, would regulatory like briefly into environment.
of Chinese XX violations news data the few over ranging breaches weeks, last have from During various antitrust instances to charged outlets government security. with where the companies reported
intent equitable the sixth, conglomerates; of only the is sensitive and that cost to deserves to amounts a Delving three, growing such from our might with developed and have innovation too address business data curbing practices concerning it antimonopoly platform that at in one preventing of that These by platform; playing large without health cost which the believe care, understanding of actions leveling aligns innovation collected pertains vast and these by set single on aimed of XXX reduce our long of costs field. business. concerns of company's the the goals. being spur short-term uniform environment the five, government's perceived believe care, is have policies, we technology. We is dominant income risk further and by uncertainty. why will all to or company to the the sell last including a care. a category government's that to conduct two, practices industry; to with health The merchants leveraging lastly, affordable the smaller stifle becoming one, as competing that the anticompetitive following: we requiring provide exclusively to oversight the access also anticompetitive in details everyone into policies practices term four, be is changes one, standards; will On help XXX, surface, desire these inequality; regional more governing which But health companies, a reducing players
and with the medium-sized expand improve tools Our their suite solutions of small- and technology businesses. to enterprise businesses and provide
unavailable Our were smaller cities. nationwide provides quality footprint and consumers also access previously rural to care services in to that health
significantly grown our practices already an XXXX, vast has policies compete. opportunities Thus, XXX equal at remain. all Although opportunity containing since and in to companies unfair for growth welcome allowing IPO aimed we
As a such, as the headwind we XXX. view a recent regulatory for than tailwind actions rather
performance. Moving on to recent
year-over-year billion, XX% the with net XXth achieve year-over-year quarter growth IPO. We of the since RMB second increasing quarter in marking results our exceptional continue to consecutive X revenue to
representing towards XXXX shareholders this increase. decreased which to marketplace online RMB have XX X.X% revenue, second growth, diversify in revenues as percentage quarter, RMB technology stream, of a are objective shows and Non-GAAP continues with and an for in seen billion year-over-year. include revenues net million, consultations, Our report primarily digital offerings, Net others. service service to totaling accounting BXB of slower our overall cloud XXXX attributable from X.X service services, QX to supply loss profitability. deliver to of We're year-over-year, revenue our progress a marketing, expenses excellent XXX% at to which year-over-year attributed was pace vendor for grew chain quarter the expenses continued BXB services, medical in e-prescription going grow a revenue net total and pleased management to as X.X% for growing we our ordinary XXX's increase R&D XX% expected that support forward. Further, up segment loss to demand these of in XXX%
In QX tools grew Gross BXB our improving addition and to optimizing categories, chain product top growing our our margins. business on of efficiency from from for to supply segment we improve implementing SaaS growing mainly are our focused laser XXXX processes. in XXX% line, margin various
partnerships make outpacing for margin this with growth to enhancing strides expanding infrastructure continue global chain internal supply with we making continue growth keep trend and efforts strides gross to improving towards revenue improve our initiatives of we our and operating expect In also pharmaceutical margins, improve conjunction domestic to our include key We as profitable. Other our to efficiency. margin companies. becoming
quarter. and marketing and selling both decreased revenue, of percentage sharply this expenses, administrative general expenses a in and As
warehouse enables efficiency an costs. each implemented of improved has significantly we Additionally, algorithm products, and lowered that high-velocity deliveries the labor which of
and we have quarter, XXXX. in are the proprietary directly on in these expenses digital SKUs. the that these of and specification China. Although our improving further laid enabling We're noted evidenced for increased XXX second purposeful also care towards companies patients for that patents technology, HawkEye around and with pharmaceutical our areas up be as for our online has capabilities operating operating doing SMART our move as includes products. also goal promote thresholds emphasis with XXX XX% By and offline to supply an digital our It This partners marketing year-over-year, healthy digital outlays and by of with new marketing RMB strong connects expenses big landscape chain technology XX our data pharmaceutical developing new growth secured tool, investing emphasis have transforming promote and the high-margin should areas. existing analytics Turbo, pharmacies a we health, special health long-term to were these expected in to foundation a so, million to solid peaked
marketing our capabilities leveraged for in developed already model also model. online sales our the We promote BXB to BXC
shows, education proprietary as live online with and Our telecast, tools, such education. consumer e-courses are training and to designed equip facilitate pharmacists to marketing
year. of our the profits. chain our and companies, prior. pharmaceutical now have created Omron partners XX% the a global XXX as supply robust efficient capacity. maximize XXX to the sourcing strengthen our strengths. XXX within hours. to from chain infrastructure, XX one Our Today, including in the we square customers to quarter, we path, pharmaceutical our growing increased supply we been with fulfillment fulfillment meters Eli To than Novartis, meet and we strategically core financial direct to start for leading partners, year, this has continue domestic always centers sourcing X second of to us end By demand more SMART to totaling doubling a than had fulfillment expanded year of we we the have of expand up services, In at approximately of Sanofi, efficiency, more directly Lilly, companies cities the number enables Bayer, to from towards plan supply of space which more amount located expanding Meanwhile, partnerships more XXX,XXX deliver capacity the such
position fulfillment this growth. While our the increase the cost short us will for future term, investment in will
XXX high our from network, which market while At increased we covered the the year of XXX,XXX XXXX, per quarter X also revenue achieving have is coverage second up We pharmacies user. average of to the in XXX,XXX a ago. XX% end pharmacies
same adding already Moving total that we -- we at the X/X forward, will in given have we're anticipate do the network be the as be to covering this of anticipate that our market. about pharmacies not do will that we past we not rate
efforts on focus we customers. relationships our However, our established existing growing with will
the demonstrates the level revenue, our existing of from customers' loyalty During quarter, of comprised total customers satisfaction. high XX% second and purchases which
therapies not strategy trends the market the term, achieving XX,XXX full in segment provide doctor-patient expectations BXC tools, provide to given products This platform consultation desired be to otherwise. remains is access of available not and affordable our to core platform and it would hospital. a a completed management over There Clinic using our medical patients medication health including short and a innovative our marketing digital care have nationwide. and to currently services Internet commitment patient upgrades online overreaching line, nationwide, While includes buildout portal, connect yet our to with X an are and which to product includes doctors the platform, we patients our representatives, education a which services that
to in As is across health to proud there of is may large bridging a aware, care part disparity in that and a country, play access you some XXX gap. the be
and in Sanofi's severe Cosentyx, progress as Eli commercialization such drug innovative psoriasis; as Novartis' plaque made XXX Taltz with Lilly's of Our platform well solid Trulicity, therapies, Dupixent has treatment which treats metastatic and plaque which and breast providing eczema. Verzenio, treat patients for psoriasis respectively; cancer, as diabetes, the
our of a the of materials well these and network to privileged in suite use early products educational digital progress centralized by new update like overwhelming success offerings. service of eclipsing exciting strategy. program access initiative, by manage has features this and would XX,XXX offering exclusive as annual that build growth benefits, expanding members program. I digital an we the around recently China procurement including as larger to stores were our delighted excited rewards allows a across the We plan Membership solutions We're further Finally, branded to achieve made businesses. franchise our have launched as response Health pharmacies their joined selection our milestone expand an that which and our and loyalty-driven X the fee This pharmacies, of to we in will initiative program a XXX provide on upon and to of help
to highlights, grows. as our continue focused but not and our innovative on also technology-enabled provide our growing Beyond business strengthen only our our capitalize margins. services team, these on top improving we We're infrastructure line
that services to in We XXX position tailwinds, well in the for and transform ultimately value leading with care service sector, are as along growth China our health we deliver industry health position care continued excellent our shareholders. confident
I to walk the will call I would Thank for our their that, continuing thank to support. Finally, Luke hand through to results. shareholders financial our you. With like
